April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Vitreous Levels of Apelin, a Novel Angiogenic Cytokine, Are Increased in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • K. B. Wise
    Retina Division, Vanderbilt Eye Institute, Nashville, Tennessee
  • H. Toma
    Retina Division, Vanderbilt Eye Institute, Nashville, Tennessee
  • L. Xu
    Retina Division, Vanderbilt Eye Institute, Nashville, Tennessee
  • F. M. Recchia
    Retina Division, Vanderbilt Eye Institute, Nashville, Tennessee
  • Footnotes
    Commercial Relationships  K.B. Wise, None; H. Toma, None; L. Xu, None; F.M. Recchia, None.
  • Footnotes
    Support  NIH (EY07533 and P30 EY08126); Unrestricted Departmental Grant from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5634. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. B. Wise, H. Toma, L. Xu, F. M. Recchia; Vitreous Levels of Apelin, a Novel Angiogenic Cytokine, Are Increased in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5634.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Proliferative diabetic retinopathy (PDR) is an increasingly common cause of vision loss resulting from retinal neovascularization. Identification of factors associated with retinal angiogenesis may lead to rational anti-angiogenic therapy. We have demonstrated upregulation of the gene apln (coding for apelin, an oxygen-sensitive cytokine required for normal vasculogenesis and for fluid homeostasis in various organ systems) in two rodent models of oxygen-induced retinopathy. This study aimed to determine whether vitreous levels of apelin were elevated in cases of PDR, in order to rationalize, by way of clinical correlation, further study of the apelin pathway in PDR pathogenesis.

Methods: : Undiluted vitreous and serum samples were obtained from patients undergoing vitreoretinal surgery for PDR and from diabetic and non-diabetic patients undergoing surgery for non-vascular disease. Concentrations of apelin and VEGF were measured in duplicate by ELISA and compared. The angiogenic effect of apelin was assessed by a tube formation assay using primary cultures of human retinal vascular endothelial cells (HRVECs) stimulated with varying concentrations of apelin (2.5 µM - 20 µM) and with 2.5 µM VEGF.

Results: : Vitreous apelin concentrations were significantly different among the three groups (PDR, non-diabetics, and diabetics without PDR; p=0.007 by ANOVA). Patients with PDR (n=21) had a mean vitreous apelin concentration of 50.3 pg/mL, while non-diabetic patients (n=33) had a mean concentration of 29.3 pg/mL (p=0.014 by Wilcoxon rank-sum). Serum concentrations of apelin did not differ significantly between PDR (367.1 pg/mL) and non-diabetic (358.8 pg/mL) groups (p=0.21). Vitreous VEGF levels differed significantly (p<0.001) between PDR patients (522.1 pg/mL) and non-diabetic patients (89.6 pg/mL). In HRVECs, 2.5 µM of recombinant apelin significantly increased capillary tube formation (total tube length of 71.0 mm vs. 25.8 mm in untreated cells, p=0.01) and to a similar degree as 2.5 µM VEGF (total tube length of 71.3 mm).

Conclusions: : Vitreous levels of apelin were significantly elevated in patients with PDR and may be released by ischemic retina, rather than diffusing from serum. The increase in vitreous apelin and its in vitro angiogenic potential, independent of VEGF, suggest that the apelin signaling pathway warrants further study as to its involvement in PDR and its potential as an antiangiogenic target.

Keywords: retinal neovascularization • diabetic retinopathy • neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.